MichBio

Could new federal biotechnology legislation reshape how life sciences companies structure partnerships and licensing agreements?

The proposed Biotechnology Innovation and National Security Act (BINSA) could expand government review of certain biotechnology transactions involving covered foreign entities.

For biotech companies, the implications may extend well beyond manufacturing and supply chains—potentially affecting licensing, collaborations, and investment decisions.

Read more: https://ow.ly/wHFN50Zbiub

What questions does your organization have about BINSA?

For nearly 80 years, Charles River Laboratories has helped advance the science behind life-changing therapies.

Our latest BioMatters® feature highlights the impact of Charles River's Mattawan, Michigan facility, where teams support drug discovery and development while investing in workforce development, community partnerships, and the next generation of life sciences talent.

The article explores how Charles River combines scientific excellence with a commitment to education, collaboration, and creating healthier lives.

Read More: https://issuu.com/michbio/docs/26-spring-biomatters-issuu/29

NIH is considering a proposal that would limit the number of simultaneous research grants held by a single principal investigator.

Supporters argue it could distribute funding across a broader group of researchers and help strengthen the biomedical workforce. Critics question whether it could unintentionally slow large-scale research efforts and collaborative programs.

If implemented, what impact would this have on research institutions, investigators, and innovation in Michigan?

Read our analysis: https://ow.ly/y9XE50ZbiCx

Share your perspective below.

More than 75 professionals from across Michigan’s life sciences community joined us on June 3 at Bell’s Eccentric Café in Kalamazoo for another fantastic BioMixer!

From biotech and medtech to research, healthcare, academia, and emerging startups, attendees came together to make new connections, strengthen existing relationships, and engage with colleagues from across the state’s growing life sciences ecosystem.

A big thank you to everyone who joined us and helped make the evening such a success. Special thanks to our host venue, Bell’s Eccentric Café, and to VWR for their continued support of the BioMixer series alongside MichBio.

We’re proud to create opportunities that bring Michigan’s life sciences community together—and we look forward to seeing you at an upcoming BioMixer soon!

BioMEMS Diagnostics has appointed noted diagnostics expert, physician, entrepreneur, and bestselling author Dr. Robert Bilkovski, MD, MBA, to its team. Dr. Bilkovski brings extensive leadership experience spanning diagnostics, medical devices, pharmaceuticals, clinical development, and regulatory strategy, further strengthening the company’s efforts to advance innovative diagnostic technologies.

READ MORE: https://ow.ly/J8Hi50Zbjtc

Mark Your Calendars, Michigan MedTech!

The 2026 Michigan Medical Device Summit is coming to Ann Arbor on September 30, 2026.

We're honored to welcome Michelle Tarver, MD, PhD, Director of CDRH at the U.S. FDA, as our keynote speaker.

From emerging technologies and product development to manufacturing, regulation, and commercialization, this event brings together the people and organizations driving Michigan's medical device ecosystem forward.

Registration opens July 6. Early rates run through August 16.

https://www.michbio.org/medical-device-summit

Looking for non-dilutive funding opportunities?

The June Government Bioscience Grants (GBG) Report by G2G - Innovative Government Affairs Consulting includes 129 funding opportunities, forecasts, notices of special interest, requests for information, and other funding resources relevant to life sciences organizations.

Whether you're a startup, researcher, entrepreneur, or established company, identifying the right funding opportunity can be a game changer.

What's your biggest challenge when pursuing government funding?

Access the June report and webinar details: https://www.michbio.org/news/june-2026-gbg-report-available

TrialAssure has announced the appointment of Dr. Oladayo Oyelola to its Advisory Board, where he will support the company’s clinical trial transparency strategy. With more than three decades of experience in clinical research, regulatory affairs, and global disclosure operations, Dr. Oyelola brings deep expertise in helping organizations navigate evolving transparency and data-sharing requirements.

Read More: https://ow.ly/BYFf50ZbjoB

San Diego is the place to be this June for BIO International Convention 2026, and our partners at Corporate Traveler are making sure every attendee arrives ready to hit the ground running.

Check out their insider travel guide for everything you need to know before, during, and after the convention.

https://ow.ly/qT0t50ZbbyR

UnDemo Day® is back! Renaissance Venture Capital’s annual event welcomes 550 venture
investors and Michigan startups to Detroit for networking and curated 1:1 meeting schedules.
Startups can apply at https://undemoapp.com to be considered for meetings with investors.